Tiotropium handihaler improves the survival of patients with COPD: A systematic review and meta-analysis

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 1, 2014, Pages 43-50

  Mathioudakis, Alexandros G ^a,b   Kanavidis, Prodromos ^a   Chatzimavridou Grigoriadou, Victoria ^a   Gialmanidis, Ioannis P ^b   Amanetopoulou, Stavroula G ^b   Christopoulou, Eleni ^b   Evangelopoulou, Efstathia ^b   Mathioudakis, Georgios A ^b  

^a Respiratory Assembly Hellenic Society for the Advancement of Biomedical Research   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

Author keywords

chronic bronchitis; COPD; emphysema; human; LAMA; mortality; Spiriva; tiotropium

Indexed keywords

CORTICOSTEROID; IPRATROPIUM BROMIDE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; FATALITY; HUMAN; INHALER; META ANALYSIS; MORTALITY; OXYGEN THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; CHI-SQUARE DISTRIBUTION; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS; SCOPOLAMINE DERIVATIVES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893134178     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.1012     Document Type: Review

References (47)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Revised 2011). Available at www.goldcopd.org/uploads/ users/files/GOLD-Report-2011-Feb21.pdf. Accessed February 14, 2013.
2. World Health Organization (WHO): The World Health Report 2000. Health Systems: Improving Performance. WHO, Geneva; 2000.
3. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, and Rutten-van Molken MP: The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164:590-596.
4. Stoller JK, Panos RJ, Krachman S, Doherty DE, Make B; Long-term Oxygen Treatment Trial Research Group: Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. Chest. 2010;138: 179-187.
5. Van den Bruel A, Gailly J, and Neyt M: Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med. 2010; 10:50.
6. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
7. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators: The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19-26.
8. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mo lken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364: 1093-1103.
9. Barr RG, Bourbeau J, Camargo CA, and Ram FS: Tiotropium for stable chronic obstructive pulmonary disease: a metaanalysis. Thorax. 2006;61:854-862.
10. Celli BR, MacNee W, and Force AET: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
11. Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, and Cassino C: Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397-404.
12. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, and Kesten S: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58: 399-404.
13. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B; INTENSITY Study Investigators: Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38:797-803.
14. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, and Witek T Jr: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
15. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, and Kesten S: Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809-817.
16. Chan CK, Maltais F, Sigouin C, Haddon JM, Ford GT; SAFE Study Group: A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J. 2007;14:465-472.
17. Covelli H, Bhattacharya S, Cassino C, Conoscenti C, and Kesten S: Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy. 2005;25:1708-1718.
18. Criner GJ, Sharafkhaneh A, Player R, Conoscenti CS, Johnson P, Keyser MT, and Cassino C: Efficacy of tiotropium inhalation powder in African-American patients with chronic obstructive pulmonary disease. COPD. 2008;5:35-41.
19. Donohue JF, Fogarty C, Lo tvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B; INHANCE Study Investigators: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
20. Dusser D, Bravo ML, and Iacono P: The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006;27:547-555.
21. Fang LZ, Liang X, Zhang JQ, Liu L, Fu WP, Zhao ZH, and Dai LM: [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial]. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31:811-814.
22. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, and Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40:1106-1114.
23. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, and Kesten S: Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102:50-56.
24. Moita J, Barbara C, Cardoso J, Costa R, Sousa M, Ruiz J, and Santos ML: Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther. 2008;21:146-151.
25. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, and Kesten S: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317-326.
26. Niewoehner DE, Lapidus R, Cote C, Sharafkhaneh A, Plautz M, Johnson P, and Kesten S: Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2009;22:587-592.
27. ODonnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, and Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-840.
28. Perng DW, Tao CW, Su KC, Tsai CC, Liu LY, and Lee YC: Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/ fluticasone or tiotropium in COPD. Eur Respir J. 2009;33:778-784.
29. Powrie DJ, Wilkinson TM, Donaldson GC, Jones P, Scrine K, Viel K, Kesten S, and Wedzicha JA: Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007;30:472-478.
30. Rabe KF, Timmer W, Sagkriotis A, and Viel K: Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008;134:255-262.
31. Rice KL, Leimer I, Kesten S, and Niewoehner DE: Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease. Transl Res. 2008;152:88-94.
32. Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M; TIPHON Study Group: Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:301-310.
33. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ; Dutch/Belgian Tiotropium Study Group: Improved health outcomes in patients with COPD during 1 yrs treatment with tiotropium. Eur Respir J. 2002;19:209-216.
34. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, and Thirlwell J: Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511-1520.
35. Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N; ATEM-Studiengruppe: [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]. Pneumologie. 2006;60:341-346.
36. Kesten S, Jara M, Wentworth C, and Lanes S: Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130:1695-1703.
37. Singh S, Loke YK, and Furberg CD: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439-1450.
38. Rodrigo GJ, and Nannini LJ: Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther. 2007;20: 495-502.
39. Karner C, Chong J, and Poole P: Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD009285.
40. Chong J, Karner C, and Poole P: Tiotropium versus longacting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD009157.
41. Nannini LJ, Lasserson TJ, and Poole P: Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
42. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, and Tashkin DP: Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137:20-30.
43. Gorecka D, Gorzelak K, Sliwinski P, Tobiasz M, and Zielinski J: Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax. 1997;52:674-679.
44. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62:411-415.
45. Singh S, Loke YK, Enright PL, and Furberg CD: Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215.
46. van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, and Fogarty C: The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med. 2009;103:22-29.
47. Comparison of tiotropium in the HandiHaler versus the Respimat in chronic obstructive pulmonary disease. 2011. Available at clinicaltrials.gov/show/ NCT01126437. Accessed February 14, 2013.